Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This was a phase 2a study of MLN1202 to determine safety, tolerability and initial efficacy
in patients with relapsing-remitting multiple sclerosis (RRMS). It was conducted in 2 dose
cohorts enrolling a total of 50 patients. Efficacy was assessed by comparing the numbers of
new gadolinium-enhancing brain lesions during the screening and treatment periods.